FDA Clearance Tracker · P910056-S054
enVista hydrophobic acrylic IOL, enVista toric hydrophobic acrylic IOL, enVista Aspire hydrophobic acrylic IOL, enVista
Last checked: Nov 20, 2026Latest source record: Jul 29, 2024 (this decision)Source: openFDAMethods & limitations
Decided
Jul 29, 2024
Approved
Time to decision
89 days
Received May 1, 2024. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P910056-S054
- Device name
- enVista hydrophobic acrylic IOL, enVista toric hydrophobic acrylic IOL, enVista Aspire hydrophobic acrylic IOL, enVista
- Applicant
- Bausch & Lomb, Inc.
- Applicant location
- Irvine, CA
- Received
- May 1, 2024
- Decided
- Jul 29, 2024
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P910056
Device type
- Device type
- intraocular lens (HQL)
- Device class
- Class III
- Regulation
- 21 CFR 886.3600
- Specialty
- Ophthalmology
FDA's approval statement
As written in FDA's record.
approval for a new packaging configuration (i.e., lens shuttle and vial ) for the enVista and enVista Aspire monofocal (toric and non-toric) hydrophobic acrylic intraocular lenses (IOL)
Source documents
Other decisions for Bausch & Lomb, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Bausch + Lomb Multifocal for Astigmatism (kalifilcon A) One-Day Soft (hydrophilic) Contact Lens510(k)
K262941 · Decided Oct 16, 2026 · 56 days after receipt
Device type: Lenses, Soft Contact, Daily Wear (LPL) · Ophthalmology
P240005 · Decided Oct 10, 2024 · 216 days after receipt
Device type: Lens, multifocal intraocular (MFK) · Ophthalmology
K192005 · Decided Oct 4, 2019 · 67 days after receipt
Device type: Folders And Injectors, Intraocular Lens (Iol) (MSS) · Ophthalmology
3 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.